Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 466 AL 480

Balancing Speed and Sensitivity: Echo-Planar Accelerated MRI for ARIA-H Screening in Anti-Aβ Therapeutics

Hagiwara A.

Invest Radiol. 2026 May 1;61(5):307-308. doi: 10.1097/RLI.0000000000001232.

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model

Bhagunde P, Penner N, Willis BA, Bell R, Charil A, Irizarry MC, Hersch S, Reyderman L.

CPT Pharmacometrics Syst Pharmacol. 2026 Feb;15(2):e70173. doi: 10.1002/psp4.70173.

Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions

Zorkina Y, Abramova O, Zubkov E, Gurina O, Ushakova V.

Int J Mol Sci. 2026 Apr 16;27(8):3560. doi: 10.3390/ijms27083560.

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Perry R, Kipps C, Soto Martín ME, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L.

J Prev Alzheimers Dis. 2026 Apr;13(4):100507. doi: 10.1016/j.tjpad.2026.100507. Epub 2026 Feb 13.

Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy

Patwekar F, Patwekar M, Wei LS, Sharma R, Varghese R, Mohammed A.

Pathol Res Pract. 2026 May;281:156421. doi: 10.1016/j.prp.2026.156421. Epub 2026 Feb 24.

Cognition, Diagnosis, and Treatment of Alzheimer's Disease: A Review

Qin Y, Deng X, Zhang S.

Recent Pat Biotechnol. 2026;20(2):260-280. doi: 10.2174/0118722083358924250606173812.

Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications

Vossel K, Johnson EL, Cretin B, Matsumoto R.

Lancet Neurol. 2026 Mar;25(3):294-307. doi: 10.1016/S1474-4422(25)00425-9. Epub 2026 Jan 22.

[Efficacy of choline alfoscerate treatment for subjective cognitive impairment in first-degree relatives of patients with Alzheimer's disease: Results of a comparative 5-year study]

Selezneva ND, Roshchina IF, Gavrilova SI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(4. Vyp. 2):92-99. doi: 10.17116/jnevro202612604292.

Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease

Farrell C, Saini F, Beidas MM, Ryan NS, Strydom A, Wiseman FK.

Alzheimers Dement. 2026 Apr;22(4):e71404. doi: 10.1002/alz.71404.

A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease

Holper S, Barnham KJ, Churilov L, Yates P, Brodtmann A, Johns S, Li QX, Bhalala O, Chin KS, Loveland P, Yu JJ, Masters CL, Watson R, Yassi N.

Alzheimers Dement. 2026 Apr;22(4):e71381. doi: 10.1002/alz.71381.

Therapeutic Options for Alzheimer's Disease and Aging-Associated Cognitive Decline: State of the Art in the ACH2.0 Paradigm

Volloch V, Rits-Volloch S.

Int J Mol Sci. 2026 Feb 2;27(3):1486. doi: 10.3390/ijms27031486.

Alcohol-Induced Dysregulation of Hydrogen Sulfide Signaling in Alzheimer's Disease-Narrative Mechanistic Synthesis Review

Munteanu C, Popescu C, Vlădulescu-Trandafir AI, Maraver F, Carbajo JM, Onose G.

Int J Mol Sci. 2026 Feb 6;27(3):1595. doi: 10.3390/ijms27031595.

Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study

Merikle E, Presnall C, Feaster T, Moxon R, Siemers E, Kerwin D, Cline S.

Trials. 2026 Mar 23;27(1):339. doi: 10.1186/s13063-026-09656-w.

Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial

Duehring JA, Jacobs DM, Salmon DP, MacKelfresh AJ, Revta C, Meyer A, Schaeffer M, Schell-Mader S, Wassmann T, Wenzkowski C, Feldman HH, Edland SD; ADCS VIVA-MIND Study Group.

J Prev Alzheimers Dis. 2026 May;13(5):100531. doi: 10.1016/j.tjpad.2026.100531. Epub 2026 Mar 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias